Volume 28, Number 4—April 2022
Research
Decrease in Tuberculosis Cases during COVID-19 Pandemic as Reflected by Outpatient Pharmacy Data, United States, 2020
Figure 3

Figure 3. Tuberculosis cases reported to the National TB Surveillance System (NTSS) and IQVIA (https://www.iqvia.com) projected patient counts in 2020 compared with previous years, United States. A seasonal autoregressive integrated moving average model was fit to January 2006–December 2019 data from cases reported to NTSS by treatment start date (A), IQVIA isoniazid projected patient counts (B), or IQVIA pyrazinamide projected patient counts (C) (for model details, see Appendix Figures 6–8). Light gray indicates model with 95% prediction intervals, which was used to forecast 2020 counts with 95% prediction intervals (dark gray). Black dots represent the number of cases (A) or projected patient counts (B, C) each month. Vertical axes in each plot are different because of different scales.